Young-onset dementia in memory clinics in the Netherlands: Study design and description of PRECODE-GP

Aniek M van Gils1,2, Hanneke F M Rhodius-Meester1,2,3,4, Anna E Leeuwis1,2

  • 1Alzheimer Center Amsterdam Department of Neurology Vrije Universiteit Amsterdam Amsterdam The Netherlands.

Insights

A new national database in the Netherlands captures data on young-onset dementia (YOD) patients under 70. This initiative aims to improve diagnosis and care for this vulnerable group, providing crucial insights into YOD characteristics.

Area of Science:

  • Neurology
  • Geriatrics
  • Public Health

Background:

  • Young-onset dementia (YOD) presents distinct challenges in disease progression and healthcare needs compared to late-onset forms.
  • Accurate epidemiological data on YOD is essential for enhancing diagnostic accuracy and optimizing patient care strategies.
  • Existing research often underrepresents YOD, necessitating dedicated data collection efforts.

Purpose of the Study:

  • To establish a prospective national database (PRECODE-GP) for patients diagnosed with young-onset dementia (YOD) in the Netherlands.
  • To investigate the incidence and clinical characteristics of YOD patients within Dutch memory clinics.
  • To lay the groundwork for future research and improved management of YOD.

Main Methods:

  • Prospective data collection from memory clinics across the Netherlands.
  • Inclusion of dementia patients diagnosed under the age of 70 years.
  • Data gathered included demographics, clinical variables, and etiological diagnoses.

Main Results:

  • A total of 781 patients were included between July 2019 and December 2022, with a mean age of 62±6 years at diagnosis.
  • Alzheimer's disease (AD) was the most common diagnosis (70%), followed by Frontotemporal lobe dementia (FTD, 11%).
  • A significant proportion (55%) of patients experienced symptoms for two years or more prior to diagnosis.

Conclusions:

  • The establishment of the PRECODE-GP database provides valuable insights into the characteristics of YOD in the Netherlands.
  • This national initiative addresses the underrepresentation of YOD in research and clinical practice.
  • The database serves as a foundation for future studies aimed at improving the diagnosis and care of young-onset dementia.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
139